MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRA in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The role of microRNA-491-5p (miR-491-5p) in human prostate cancer (PCa) is currently unknown.
• Previous studies have linked miR-491-5p to various cancers, but its specific function in PCa requires elucidation.

Purpose of the Study:

• To investigate the expression and function of miR-491-5p in human prostate cancer.
• To identify the molecular mechanisms underlying miR-491-5p's role in PCa progression.
• To evaluate the potential of miR-491-5p as a diagnostic or therapeutic biomarker for PCa.

Main Methods:

• Quantitative real-time PCR to assess miR-491-5p expression in PCa tissues and cell lines.
• Cell proliferation assays (CCK-8, EdU) and cell cycle analysis to evaluate the impact of miR-491-5p on PCa cell growth.
• Transwell assays to measure the effects of miR-491-5p on PCa cell migration and invasion.
• In vivo studies using a mouse xenograft model to assess the anti-tumor efficacy of miR-491-5p.
• Western blotting and luciferase reporter assays to identify and validate PDGFRA as a direct target of miR-491-5p.

Main Results:

• miR-491-5p expression was significantly downregulated in PCa tissues and cell lines compared to normal controls.
• Forced expression of miR-491-5p suppressed PCa cell proliferation, induced cell cycle arrest, and reduced migration and invasion.
• Overexpression of miR-491-5p significantly inhibited tumor growth in a mouse xenograft model.
• Platelet-derived growth factor receptor α (PDGFRA) was identified as a direct target of miR-491-5p.
• PDGFRA re-introduction reversed the inhibitory effects of miR-491-5p on PCa cell proliferation and motility.
• miR-491-5p expression was negatively correlated with PDGFRA expression in clinical PCa samples, with PDGFRA being upregulated in PCa.

Conclusions:

• miR-491-5p functions as a tumor suppressor in prostate cancer.
• The tumor-suppressive activity of miR-491-5p is mediated through the direct inhibition of PDGFRA.
• miR-491-5p may serve as a potential therapeutic biomarker for prostate cancer patients.